Skip to market wire
Back to Market返回行情

HBIO Harvard Bioscience, Inc.

USHealthcare
$8.24+1.35%ClosedMarket Cap: $37.2M

As of 2026-10-09

Why HBIO matters now

Harvard Bioscience, Inc. (HBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.24 with +1.35% on the session and $37.2M in market capitalization; recent performance reads 1-month +17.17% and YTD -12.26%.

The latest financial table shown here is Q1 2026, with revenue of $20.8M, net income of $-3.4M, and EPS of $-0.77. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 5.7%.

The latest indexable market news headline is "Harvard Bioscience Announces Creation of Scientific Advisory Board" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00; recent insider activity includes Eade Katherine A. filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

2.61

P/S

0.31

EV/EBITDA

-33.96

DCF Value

$-19.34

FCF Yield

5.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

57.1%

Operating Margin

1.4%

Net Margin

-11.4%

ROE

-73.0%

ROA

-12.6%

ROIC

2.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$20.8M$-3.4M$-0.77
Q4 2025$23.7M$-2.8M$-0.64
FY 2025$86.5M$-56.7M$-12.80
Q3 2025$20.6M$-1.2M$-0.28

Analyst Ratings

Consensus

Hold

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

Strong Buy: 1Buy: 0Hold: 1Sell: 0Strong Sell: 0
BenchmarkSpeculative Buy
2026-03-16
BenchmarkSpeculative Buy
2025-09-10

Trading Activity

Insider Trades

Eade Katherine A.director
Sell2026-06-12
Benson Seth Benjamindirector
Sell2026-06-11
Gagnon Robert E.director
Sell2026-06-11
DENELSKY STEPHEN Jdirector
Sell2026-06-11
Snider Williamdirector
Sell2026-06-11

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

—

Beta

1.51

Harvard Bioscience, Inc. (HBIO) is a global provider of cutting-edge technologies, products, and services crucial for fundamental scientific investigation, drug discovery, and preclinical testing. Serving both domestic and international markets, the company supplies an extensive range of cellular and molecular instruments. This includes precision fluid handling devices like syringe and peristaltic pumps, alongside a variety of tools and accessories for tissue and organ-based laboratory research, such as surgical instruments, infusion systems, and behavioral analysis setups. Their portfolio also encompasses analytical equipment like spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis units, and electroporation/electrofusion instruments. Moreover, Harvard Bioscience specializes in developing and manufacturing advanced scientific measuring instrumentation, featuring sophisticated data acquisition systems with customizable amplifier configurations for cellular analysis, microelectrode array solutions for in vivo recordings, and in vitro systems for extracellular studies, in addition to a full suite of preclinical products. The company markets its offerings through direct sales teams, online channels, catalogs, and authorized distributors. Their diverse customer base includes research scientists within pharmaceutical and biotechnology companies, academic institutions (universities, colleges), hospitals, government laboratories, and contract research organizations. Products are sold under well-known brand names such as Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. Founded in 1901, Harvard Bioscience, Inc. is headquartered in Holliston, Massachusetts.